GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » Days Payable

RYTM (Rhythm Pharmaceuticals) Days Payable : 303.17 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Days Payable?

Rhythm Pharmaceuticals's average Accounts Payable for the three months ended in Mar. 2025 was $12.1 Mil. Rhythm Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2025 was $3.6 Mil. Hence, Rhythm Pharmaceuticals's Days Payable for the three months ended in Mar. 2025 was 303.17.

The historical rank and industry rank for Rhythm Pharmaceuticals's Days Payable or its related term are showing as below:

RYTM' s Days Payable Range Over the Past 10 Years
Min: 189.96   Med: 568.14   Max: 3240.82
Current: 211.76

During the past 10 years, Rhythm Pharmaceuticals's highest Days Payable was 3240.82. The lowest was 189.96. And the median was 568.14.

RYTM's Days Payable is ranked better than
64.35% of 704 companies
in the Biotechnology industry
Industry Median: 118.35 vs RYTM: 211.76

Rhythm Pharmaceuticals's Days Payable increased from Mar. 2024 (202.12) to Mar. 2025 (303.17). It may suggest that Rhythm Pharmaceuticals delayed paying its suppliers.


Rhythm Pharmaceuticals Days Payable Historical Data

The historical data trend for Rhythm Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Days Payable Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3,240.82 901.29 189.96 234.99

Rhythm Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 202.12 187.22 112.39 207.40 303.17

Competitive Comparison of Rhythm Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Days Payable falls into.


;
;

Rhythm Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Rhythm Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

Days Payable (A: Dec. 2024 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2023 ) + Accounts Payable (A: Dec. 2024 )) / count ) / Cost of Goods Sold (A: Dec. 2024 )*Days in Period
=( (4.885 + 12.328) / 2 ) / 13.368*365
=8.6065 / 13.368*365
=234.99

Rhythm Pharmaceuticals's Days Payable for the quarter that ended in Mar. 2025 is calculated as:

Days Payable (Q: Mar. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2024 ) + Accounts Payable (Q: Mar. 2025 )) / count ) / Cost of Goods Sold (Q: Mar. 2025 )*Days in Period
=( (12.328 + 11.912) / 2 ) / 3.648*365 / 4
=12.12 / 3.648*365 / 4
=303.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Executives
Pamela J. Cramer officer: Chief Human Resources Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Yann Mazabraud officer: EVP, Head of International C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Christopher Paul German officer: Corporate Controller & CAO C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Joseph Shulman officer: Chief Technical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith officer: CFO and Treasurer C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien officer: EVP, Head of North America C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Jennifer L Good director 15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
William T. Roberts officer: Chief Accounting Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning officer: Chief Medical Officer C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan officer: Chief Commercial Officer 82 BAY STATE ROAD, BELMONT MA 02478